The US drug regulator has completed a pre-approval inspection at Emcure’s Ahmedabad oncology facility without issuing a Form ...

Capricor Therapeutics is expected to release data from the phase 3 HOPE-3 trial in Q3'25, thus presenting a potential path ...

Emcure Pharma share price rose in trade after the company announced that United States Food and Drug Administration (USFDA) ...

Pune: Emcure Pharma has announced that the United States Food and Drug Administration (USFDA) has concluded a Pre-Approval ...

Emcure Pharmaceuticals advanced 1.25% to Rs 1,271.85 after U.S. Food and Drug Administration (USFDA) conducted pre-approval inspection (PAI) at its manufacturing facility (Oncology) located at G.I.D.C ...

The US FDA had conducted Pre-Approval Inspection of Emcure Pharmaceuticals Limited's manufacturing facility (Oncology) located at G.I.D.C., Taluka - Sanand, Ahmedabad - 382110, Gujarat, from June 30, ...

The Kenya Bureau of Standards (Kebs) wants a case challenging a lucrative tender for inspection of goods before leaving the ...

Enhance FDA compliance with our expanded training on inspection processes, common issues, and strategies for prevention. Gain insights into Form 483 and warning letter prevention, root cause analysis, ...

But for migrant farm ­workers, the extreme ­summer heat plagues them from their place of work into their employer-provided ...

FDA issued Complete Response Letter Capricor plans to resubmit its BLA to include data from the ongoing Phase 3 HOPE-3 trial ...

The Inter-Ministerial Group is expected to examine the share purchase agreement (SPA) for IDBI Bank, after which it will be ...

Capricor Therapeutics (CAPR) on Friday said the U.S. Food and Drug Administration (FDA) has refused to approve its lead cell ...